Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

George Abu-Aita

Neurology Hobart, IN Medical Doctor

NPI 1710997929 CMS profile 305380

1600 S Lake Park Ave Ste 1102, Hobart, IN 46342

Open in the dashboard

General payments

$4,796

321 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, George Abu-Aita of Hobart, IN is reported in the CMS Open Payments database as having received $4,796 across 321 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $80 6
2022 General $1,275 92
2021 General $1,622 103
2020 General $993 64
2019 General $826 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Abu-Aita
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to George Abu-Aita were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year George Abu-Aita Neurology median Middle half National median
2019 $826 $474 $118–$2,177 $163
2020 $993 $367 $82–$2,309 $114
2021 $1,622 $438 $104–$2,547 $132
2022 $1,275 $442 $103–$2,388 $149
2023 $80 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AbbVie, Inc. $700 55 payments
  2. Novartis Pharmaceuticals Corporation $529 34 payments
  3. Sunovion Pharmaceuticals Inc. $488 29 payments
  4. Janssen Pharmaceuticals, Inc $332 18 payments
  5. Genzyme Corporation $321 23 payments
  6. Supernus Pharmaceuticals, Inc. $321 31 payments
  7. SK Life Science, Inc. $249 18 payments
  8. Lilly USA, LLC $166 8 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $146 10 payments
  10. Lundbeck LLC $143 7 payments
  11. Other $1,401 88 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $4,663 318 payments
  2. Education $121 2 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $13 1 payment
Products named General payments · program years 2019–2023
  1. UBRELVY $627 48 payments
  2. APTIOM $488 29 payments
  3. AUBAGIO $305 22 payments
  4. AIMOVIG $297 16 payments
  5. NURTEC ODT $262 16 payments
  6. TROKENDI XR $224 23 payments
  7. Ponvory $202 10 payments
  8. KESIMPTA $180 13 payments
  9. MAYZENT $160 12 payments
  10. VYEPTI $143 7 payments
  11. Other $1,748 120 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

321 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record